The National Cancer Institute has awarded BellBrook Labs $180,000 SBIR Phase I grant to pursue the development of Transcreener™ Kinase Assay, a generic fluorescent HTS assay for protein kinases. Kinase malfunction has been linked to all of the most prominent therapeutic areas, including cancer, cardiovascular diseases, inflammation, neurodegenerative diseases and metabolic disorders. Limitations in current technologies are hampering efforts to efficiently incorporate new kinases into high throughput screens and to effectively generate quick and meaningful data.
In a response to these shortcomings, BellBrook Labs is developing a universal kinase assay based on their proprietary Transcreener™ HTS Assay platform. The Transcreener™ Kinase Assay, unique in flexibility and universality, will enable pharmaceutical companies to accelerate development of new drugs with fewer side effects for cancer and other diseases by providing an assay that can be used with any kinase and any acceptor substrate.
BellBrook Labs develops high throughput screening tools that accelerate the discovery of more effective therapies. The proprietary technology, Transcreener™ HTS assay platform is a universal, homogeneous assay that uses a single set of detection reagents across a family of enzymes, thus enabling the seamless incorporation of hundreds of new drug targets into HTS format. The benefits are clear: lowered development costs, accelerated discovery, standardized methodology, and eliminated delays. The Transcreener™ HTS assay platform will change the metrics of HTS.
Contact us at 866.313.7881 or email@example.com for more information.
Biology at Work